Piper Sandler Bullish on Axsome Therapeutics (AXSM) Ahead of Likely Auvelity Label Expansion by April 30

Axsome Therapeutics Inc. (NASDAQ:AXSM) is one of the best mid-cap growth stocks to buy right now. On January 16, Piper Sandler raised its price target on Axsome Therapeutics to $223 from $148 with an Overweight rating. Piper Sandler is confident in Auvelity’s commercial potential, particularly given the highly likely FDA label expansion into Alzheimer’s agitation expected by April 30 this year. The optimism is further supported by the drug’s sustained momentum in the depression market and a long-term patent runway that secures market exclusivity through 2039.

On January 13, Baird also raised its price target for Axsome Therapeutics from $157 to $209, while maintaining an Outperform rating. This target revision was driven by the firm’s update to its financial model following the release of preliminary Q4 2025 results that featured a slight beat compared to expectations.

Furthermore, Wells Fargo raised its price target for Axsome Therapeutics Inc. (NASDAQ:AXSM) from $157 to $193 while maintaining an Overweight rating. The firm noted that Q4 2025 sales for Auvelity and Sunosi exceeded consensus estimates, a trend it believes will drive continued positive momentum for the stock. Additionally, Wells Fargo increased its probability of success for ADA (Alzheimer’s Disease Agitation) from 75% to 90% following the FDA’s decision to grant a priority review.

Axsome Therapeutics Inc. (NASDAQ:AXSM) is a biopharmaceutical company that develops and delivers novel therapies for the management of central nervous system/CNS disorders in the US.

While we acknowledge the potential of AXSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.